These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

835 related items for PubMed ID: 15917335

  • 1. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.
    Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M.
    J Am Soc Nephrol; 2005 Jul; 16(7):2205-15. PubMed ID: 15917335
    [Abstract] [Full Text] [Related]

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 3. Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications.
    Damasiewicz MJ, Toussaint ND, Polkinghorne KR.
    Nephrology (Carlton); 2011 Mar; 16(3):261-8. PubMed ID: 21265930
    [Abstract] [Full Text] [Related]

  • 4. Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases.
    Imanishi Y, Kobayashi K, Kawata T, Inaba M, Nishizawa Y.
    Ther Apher Dial; 2007 Oct; 11 Suppl 1():S32-7. PubMed ID: 17976083
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Evaluation of human fibroblast growth factor 23 (FGF-23) C-terminal and intact enzyme-linked immunosorbent-assays in end-stage renal disease patients.
    Fassbender WJ, Brandenburg V, Schmitz S, Sandig D, Simon SA, Windolf J, Stumpf UC.
    Clin Lab; 2009 Oct; 55(3-4):144-52. PubMed ID: 19462937
    [Abstract] [Full Text] [Related]

  • 7. Fibroblast growth factor-23 is regulated by 1alpha,25-dihydroxyvitamin D.
    Collins MT, Lindsay JR, Jain A, Kelly MH, Cutler CM, Weinstein LS, Liu J, Fedarko NS, Winer KK.
    J Bone Miner Res; 2005 Nov; 20(11):1944-50. PubMed ID: 16234967
    [Abstract] [Full Text] [Related]

  • 8. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease.
    Stubbs J, Liu S, Quarles LD.
    Semin Dial; 2007 Nov; 20(4):302-8. PubMed ID: 17635819
    [Abstract] [Full Text] [Related]

  • 9. Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease?
    Peiskerová M, Kalousová M, Kratochvílová M, Dusilová-Sulková S, Uhrová J, Bandúr S, Malbohan IM, Zima T, Tesar V.
    Kidney Blood Press Res; 2009 Nov; 32(4):276-83. PubMed ID: 19797911
    [Abstract] [Full Text] [Related]

  • 10. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
    Martin KJ, González EA.
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
    [Abstract] [Full Text] [Related]

  • 11. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the "trade-off" hypothesis.
    Gutiérrez OM.
    Clin J Am Soc Nephrol; 2010 Sep; 5(9):1710-6. PubMed ID: 20507957
    [Abstract] [Full Text] [Related]

  • 12. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
    Cozzolino M, Brancaccio D.
    Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
    [Abstract] [Full Text] [Related]

  • 13. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.
    Evenepoel P, Meijers B, Viaene L, Bammens B, Claes K, Kuypers D, Vanderschueren D, Vanrenterghem Y.
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1268-76. PubMed ID: 20448073
    [Abstract] [Full Text] [Related]

  • 14. Emerging topics in pediatric bone and mineral disorders 2008.
    McKay CP, Portale A.
    Semin Nephrol; 2009 Jul; 29(4):370-8. PubMed ID: 19615558
    [Abstract] [Full Text] [Related]

  • 15. Role of vitamin D deficiency in chronic kidney disease.
    Gal-Moscovici A, Sprague SM.
    J Bone Miner Res; 2007 Dec; 22 Suppl 2():V91-4. PubMed ID: 18290730
    [Abstract] [Full Text] [Related]

  • 16. Bone and mineral metabolism and fibroblast growth factor 23 levels after kidney donation.
    Young A, Hodsman AB, Boudville N, Geddes C, Gill J, Goltzman D, Jassal SV, Klarenbach S, Knoll G, Muirhead N, Prasad GV, Treleaven D, Garg AX, Donor Nephrectomy Outcomes Research (DONOR) Network.
    Am J Kidney Dis; 2012 Jun; 59(6):761-9. PubMed ID: 22093959
    [Abstract] [Full Text] [Related]

  • 17. Fibroblast growth factor 23--structure, function and role in kidney diseases.
    Kocełak P, Olszanecka-Glinianowicz M, Chudek J.
    Adv Clin Exp Med; 2012 Jun; 21(3):391-401. PubMed ID: 23214203
    [Abstract] [Full Text] [Related]

  • 18. Pathophysiology of calcium and phosphate metabolism impairment in chronic kidney disease.
    Cozzolino M, Ciceri P, Volpi EM, Olivi L, Messa PG.
    Blood Purif; 2009 Jun; 27(4):338-44. PubMed ID: 19295196
    [Abstract] [Full Text] [Related]

  • 19. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients.
    Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C.
    Nephrol Dial Transplant; 2009 Sep; 24(9):2792-6. PubMed ID: 19395730
    [Abstract] [Full Text] [Related]

  • 20. Vascular changes in chronic renal disease patients with secondary hyperparathyroidism.
    Bortotolotto LA, Costa-Hong V, Jorgetti V, Consolim-Colombo F, Rosa K, Silva BC, Krieger EM, De Lima JJ.
    J Nephrol; 2007 Sep; 20(1):66-72. PubMed ID: 17347976
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.